Repatha was linked to a 20% lower heart attack risk than Ezetimibe in a large study of people receiving routine care. Amgen, Repatha’s maker, reported the finding in a company announcement. The study compared people using Repatha with those using Ezetimibe, another cholesterol-lowering medicine. The provided excerpt does not give their ages, study size, or follow-up time. It also does not describe how similar the two groups were. Repatha is an injection also called evolocumab. It belongs to PCSK9 Inhibitors, medicines that help the liver clear LDL Cholesterol from the blood. The key finding concerns heart attacks, not just a lower blood test number. The 20% figure compares risk between groups. It does not mean 20 fewer heart attacks per 100 people. The excerpt does not give each group’s heart attack rate. Without those rates, we cannot tell how many fewer people had one. Nor does this summary establish that the medicine alone caused the difference. Amgen also cites 15 years of study across 51 trials involving over 57,000 people. Those numbers describe Repatha’s broader evidence, not this specific comparison. For BioSocial members, this offers a reason to connect lab trends with longer-term goals. Tracking results alongside medicine start dates can make community comparisons more useful. Starting levels, time between tests, and other medicine changes add important context. A personal blood test trend, though, cannot show an individual’s change in heart attack risk. What changes have you seen in your LDL Cholesterol numbers since starting Repatha, and over what time frame?